Page 12 - Diamond Light Source News Today

THE first-ever facility handling radioactive materials has opened at the Harwell Science and Innovation Campus in Didcot.

Researchers have solved the structure of the influenza virus' replication machinery, giving structural insights into new potential drug targets and how the virus adapts to different hosts.

Renowned scientist Dr Adrian Mancuso, a well-known figure in the light sources’ community has joined the UK’s national synchrotron, Diamond Light Source, as the new Physical Science Director with responsibility for the overall strategic leadership and management of the division. Click to read more...

Adrian Mancuso has been appointed as the physical science director for the United Kingdom’s national synchrotron, Diamond Light Source. Mancuso

Dirty windows can harbour potentially harmful pollutants under protective films of fatty acids from cooking emissions – and these can hang around over long periods of time. Click to read more...

The global demand for drug discovery services market is expected to rise at a 14.5% CAGR to acquire a valuation of US$ 50.9 Bn by the end of forecast period 2022-232. The global drug discovery services market size was valued at US$ 15.5 Bn in 2021 and is projected to reach a valuation of US$ 32 Bn by 2026The global...

The consortium’s strategy is to create an AI-driven Structure-enabled Antiviral Platform (ASAP), using cutting-edge technology such as advanced structural biology, fragment screening, AI and machine learning, as well as computational chemistry on Folding@home, the world’s largest distributed computing platform to build a robust and open access antiviral discovery pipeline. Click to read more...

EQS-News: Proteros biostructures GmbH / Key word(s): Alliance Proteros and Adrestia initiate multi-target partnership to discover first-in-class drugs for intractable genetic diseases 25.10.2022

Drug discovery leader Dr James Osborne brings strong track record of delivering drug candidates for oncology and CNS disorders Proteros selected for its cutting-edge structure-based drug

The new figures released today are straightforward updates to the 2021 study by Technopolis using published methodologies where they measured and demonstrated Diamond’s scientific, technological, societal, and economic benefits.  The report summarised the findings and the updated figures - including the £2.